Industry / Germany
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Patent Ruling Blow For Yasmin
March 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Shares in German drug giant Bayer have fallen after a US district court ruled that the patent on its blockbuster oral contraceptive Yasmin (drospirenone and ethinyl estradiol) is invalid. The decision paves the way for US-based Barr Laboratories to introduce a low-cost generic version.